Cerus Corporation
A blood-safety company based in Concord, California, Cerus makes the INTERCEPT Blood System, a technology used by blood banks to zap donated platelets and plasma with UV light and a compound called amotosalen, neutralizing viruses, bacteria, and parasites before they reach patients. Founded in 1991 by hematologist Laurence Corash and chemist John Hearst, the company spun off its immunotherapy business in 2007 to focus on blood safety. Its product is aptly named: the system "intercepts" pathogens by cross-linking their DNA so they can't reproduce, rather than just screening for known ones.
Granted 1.39M · Sold 525.9K
Granted 500.3K · Sold 232.6K
Granted 563.9K · Sold 210.6K
Granted 555.2K · Sold 85.8K
Granted 319.2K · Sold 227.6K
Granted 60.0K
Granted 60.0K
Granted 60.0K · Sold 20.5K
Granted 60.0K
Granted 60.0K
Granted 60.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Greenman William MarinerPresident and CEO, Director · 4 transactions | +21.4% | 5.00M | 1.39M | — | 525.9K |
| Jayaraman Vivek KChief Operating Officer · 6 transactions | +15.7% | 1.66M | 500.3K | — | 232.6K |
| Green Kevin DennisChief Financial Officer · 6 transactions | +41.6% | 1.24M | 563.9K | — | 210.6K |
| Jensen ChrystalChief Legal Officer · 5 transactions | +46.3% | 1.15M | 555.2K | — | 85.8K |
| Benjamin Richard JChief Medical Officer · 6 transactions | +13.4% | 777.4K | 319.2K | — | 227.6K |
| Witney FrankDirector · 1 transaction | +21.4% | 340.1K | 60.0K | — | — |
| Nachtsheim Jami KDirector · 1 transaction | +28.8% | 268.4K | 60.0K | — | — |
| Bjerkholt EricDirector · 2 transactions | +17.8% | 261.7K | 60.0K | — | 20.5K |
| Lucena AnnDirector · 1 transaction | +34.8% | 232.3K | 60.0K | — | — |
| Shan HuaDirector · 1 transaction | +45.3% | 192.4K | 60.0K | — | — |
| Gregory Dean A.Director · 1 transaction | +69.2% | 146.7K | 60.0K | — | — |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last year: -1.30M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.